摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

4-(5-Hydroxy-4-oxo-4H-chromene-2-carbonyl)-piperazine-1-carboxylic acid tert-butyl ester | 868836-98-0

中文名称
——
中文别名
——
英文名称
4-(5-Hydroxy-4-oxo-4H-chromene-2-carbonyl)-piperazine-1-carboxylic acid tert-butyl ester
英文别名
Tert-butyl 4-(5-hydroxy-4-oxochromene-2-carbonyl)piperazine-1-carboxylate
4-(5-Hydroxy-4-oxo-4H-chromene-2-carbonyl)-piperazine-1-carboxylic acid tert-butyl ester化学式
CAS
868836-98-0
化学式
C19H22N2O6
mdl
——
分子量
374.393
InChiKey
IXYMYGBJEMROPF-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    2.1
  • 重原子数:
    27
  • 可旋转键数:
    3
  • 环数:
    3.0
  • sp3杂化的碳原子比例:
    0.42
  • 拓扑面积:
    96.4
  • 氢给体数:
    1
  • 氢受体数:
    6

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量
  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    4-(5-Hydroxy-4-oxo-4H-chromene-2-carbonyl)-piperazine-1-carboxylic acid tert-butyl ester三氟乙酸 作用下, 以 二氯甲烷 为溶剂, 反应 15.0h, 以26%的产率得到5-Hydroxy-2-(piperazine-1-carbonyl)chromen-4-one
    参考文献:
    名称:
    Piperazinobenzopyranones and Phenalkylaminobenzopyranones:  Potent Inhibitors of Breast Cancer Resistance Protein (ABCG2)
    摘要:
    In continuing research that led us to identify chromanone derivatives (J. Med. Chem. 2003, 46, 2125) as P-glycoprotein inhibitors, we obtained analogues able to modulate multidrug resistance (MDR) mediated by the breast cancer resistance protein (BCRP). The linkage of 5-hydroxybenzopyran-4-one to piperazines or phenalkylainines affords highly potent inhibitors of BCRP. By using sensitive (HCT116) and resistant colon cancer cells expressing BCRP, we evaluated the effect of 14 benzopyranone (chromone) derivatives on the accumulation and the cytotoxic effect of the anticancer drug, mitoxantrone. At 10 mu M, three compounds increased both intracellular accumulation and cytotoxicity of mitoxantrone in HCT116/R cells with a comparable rate as fumitremorgin C and Gleevec used as reference inhibitors. The most potent molecules 5b and 5c are still active at 1 mu M, whereas FTC shows weak inhibition. These molecules do not induce cell death as shown by the cell cycle distribution study, which makes them potential candidates for in vivo studies.
    DOI:
    10.1021/jm050705h
  • 作为产物:
    描述:
    5-羟基-4-氧代-4H-色烯-2-羧酸N-Boc-哌嗪1-(3-二甲基氨基丙基)-3-乙基碳二亚胺三乙胺 作用下, 以 四氢呋喃 为溶剂, 反应 24.0h, 以19%的产率得到4-(5-Hydroxy-4-oxo-4H-chromene-2-carbonyl)-piperazine-1-carboxylic acid tert-butyl ester
    参考文献:
    名称:
    Piperazinobenzopyranones and Phenalkylaminobenzopyranones:  Potent Inhibitors of Breast Cancer Resistance Protein (ABCG2)
    摘要:
    In continuing research that led us to identify chromanone derivatives (J. Med. Chem. 2003, 46, 2125) as P-glycoprotein inhibitors, we obtained analogues able to modulate multidrug resistance (MDR) mediated by the breast cancer resistance protein (BCRP). The linkage of 5-hydroxybenzopyran-4-one to piperazines or phenalkylainines affords highly potent inhibitors of BCRP. By using sensitive (HCT116) and resistant colon cancer cells expressing BCRP, we evaluated the effect of 14 benzopyranone (chromone) derivatives on the accumulation and the cytotoxic effect of the anticancer drug, mitoxantrone. At 10 mu M, three compounds increased both intracellular accumulation and cytotoxicity of mitoxantrone in HCT116/R cells with a comparable rate as fumitremorgin C and Gleevec used as reference inhibitors. The most potent molecules 5b and 5c are still active at 1 mu M, whereas FTC shows weak inhibition. These molecules do not induce cell death as shown by the cell cycle distribution study, which makes them potential candidates for in vivo studies.
    DOI:
    10.1021/jm050705h
点击查看最新优质反应信息

文献信息

  • Piperazinobenzopyranones and Phenalkylaminobenzopyranones:  Potent Inhibitors of Breast Cancer Resistance Protein (ABCG2)
    作者:Ahcène Boumendjel、Edwige Nicolle、Thomas Moraux、Bastien Gerby、Madeleine Blanc、Xavier Ronot、Jean Boutonnat
    DOI:10.1021/jm050705h
    日期:2005.11.1
    In continuing research that led us to identify chromanone derivatives (J. Med. Chem. 2003, 46, 2125) as P-glycoprotein inhibitors, we obtained analogues able to modulate multidrug resistance (MDR) mediated by the breast cancer resistance protein (BCRP). The linkage of 5-hydroxybenzopyran-4-one to piperazines or phenalkylainines affords highly potent inhibitors of BCRP. By using sensitive (HCT116) and resistant colon cancer cells expressing BCRP, we evaluated the effect of 14 benzopyranone (chromone) derivatives on the accumulation and the cytotoxic effect of the anticancer drug, mitoxantrone. At 10 mu M, three compounds increased both intracellular accumulation and cytotoxicity of mitoxantrone in HCT116/R cells with a comparable rate as fumitremorgin C and Gleevec used as reference inhibitors. The most potent molecules 5b and 5c are still active at 1 mu M, whereas FTC shows weak inhibition. These molecules do not induce cell death as shown by the cell cycle distribution study, which makes them potential candidates for in vivo studies.
查看更多